{"id":357,"date":"2026-05-19T16:52:10","date_gmt":"2026-05-19T16:52:10","guid":{"rendered":"https:\/\/www.libertymanagement.us\/fda-support\/?p=357"},"modified":"2026-05-19T16:52:10","modified_gmt":"2026-05-19T16:52:10","slug":"fda-cosmetic-regulations-under-mocra","status":"publish","type":"post","link":"https:\/\/www.libertymanagement.us\/fda-support\/2026\/05\/19\/fda-cosmetic-regulations-under-mocra\/","title":{"rendered":"FDA Cosmetic Regulations Under MoCRA"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">The Modernization of Cosmetics Regulation Act of 2022,\nknown as MoCRA, is an important update to US <a href=\"https:\/\/www.fdahelp.us\/cosmetics.html\">cosmetic<\/a> regulations. It gives\nthe FDA broader authority over cosmetic facility registration, product listing,\nadverse event reporting, safety substantiation, and GMP requirements.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Earlier, cosmetics were regulated less aggressively than\ndrugs and medical devices. MoCRA ensures that cosmetic companies follow a more\nformal regulatory system that covers their product from manufacturing to post\nmarket monitoring. The FDA now has stronger tools to inspect, request records,\nand enforce compliance when safety concerns arise.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">MoCRA requires cosmetic manufacturers and processors to <a href=\"https:\/\/www.fdahelp.us\/fda-mocra-registration-listing-cosmetic-facility.html\">register\ntheir facilities<\/a> with FDA and renew that registration every two years. It\nalso requires <a href=\"https:\/\/www.fdahelp.us\/mocra-fda-listing-update.html\">product\nlisting<\/a>, which means submitting product and ingredient information to FDA. <a href=\"https:\/\/www.fdahelp.us\/cosmetics-label-review.html\">Label Compliance<\/a>,\nAdverse event reporting and safety substantiation are also important compliance\nrequirements.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">MoCRA generally applies to cosmetics manufactured or\nprocessed for sale in the US, including products made outside the country. That\nmeans foreign manufacturers, importers, and responsible persons may all have\ncompliance obligations if their products enter the US market.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">There are some small-business exemptions, but those\nexemptions do not cover every product type.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Liberty Management Group Ltd can help with Cosmetic\nFacility Registration, Cosmetic Product Listings and label compliance.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Namrata <\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Regulatory\nConsultant<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>support@libertymanagement.us<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"http:\/\/www.fdahelp.us\">http:\/\/www.fdahelp.us<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Modernization of Cosmetics Regulation Act of 2022, known as MoCRA, is an important update to US cosmetic regulations. It gives the FDA broader authority over cosmetic facility registration, product listing, adverse event reporting, safety substantiation, and GMP requirements. Earlier, cosmetics were regulated less aggressively than drugs and medical devices. MoCRA ensures that cosmetic companies &hellip; <a href=\"https:\/\/www.libertymanagement.us\/fda-support\/2026\/05\/19\/fda-cosmetic-regulations-under-mocra\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;FDA Cosmetic Regulations Under MoCRA&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[36,8,70],"class_list":["post-357","post","type-post","status-publish","format-standard","hentry","category-cosmetics-regulations","tag-cosmetic-labelling","tag-label-compliance","tag-mocra"],"_links":{"self":[{"href":"https:\/\/www.libertymanagement.us\/fda-support\/wp-json\/wp\/v2\/posts\/357","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.libertymanagement.us\/fda-support\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.libertymanagement.us\/fda-support\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.libertymanagement.us\/fda-support\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.libertymanagement.us\/fda-support\/wp-json\/wp\/v2\/comments?post=357"}],"version-history":[{"count":1,"href":"https:\/\/www.libertymanagement.us\/fda-support\/wp-json\/wp\/v2\/posts\/357\/revisions"}],"predecessor-version":[{"id":358,"href":"https:\/\/www.libertymanagement.us\/fda-support\/wp-json\/wp\/v2\/posts\/357\/revisions\/358"}],"wp:attachment":[{"href":"https:\/\/www.libertymanagement.us\/fda-support\/wp-json\/wp\/v2\/media?parent=357"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.libertymanagement.us\/fda-support\/wp-json\/wp\/v2\/categories?post=357"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.libertymanagement.us\/fda-support\/wp-json\/wp\/v2\/tags?post=357"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}